Full Text View
Tabular View
No Study Results Posted
Related Studies
Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy
This study is ongoing, but not recruiting participants.
Study NCT01489904   Information provided by Hospital Vall d'Hebron

First Received on November 29, 2011.   Last Updated on October 28, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sialorrhea
Cerebral Palsy
Additional conditions recognized in this trial
Paralysis
More general conditions related to this trial
Brain Damage, Chronic
Brain Diseases
Central Nervous System Diseases
Mouth Diseases
Nervous System Diseases
Neurologic Manifestations
Salivary Gland Diseases
Signs and Symptoms
Stomatognathic Diseases
Interventions listed in this trial
BOTULINUM NEUROTOXIN TYPE-A
Additional drug interventions recognized in this trial
Botulinum Toxins
Botulinum Toxins, Type A
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Central Nervous System Agents
Neuromuscular Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Hospital Vall d'Hebron
Allergan


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services